RIGHTWARE
4.1.2022 08:02:14 CET | Business Wire | Press release
Rightware today released Kanzi One, concluding a highly successful and oversubscribed beta program announced in September. The first automotive HMI toolchain to be fully compatible with Android™, Kanzi One delivers industry-leading 3D graphics and a new UI workflow, empowering automakers to create compelling new user experiences with visual excellence and maximum productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005425/en/
“As announced at IAA in Munich, Kanzi One is a game-changer for creativity and productivity by automakers,” said Rightware CEO Freddie Geier. “We are grateful for the positive feedback from customers and partners since our product launch, and we eagerly await the new Signature UIs they create with Kanzi One.”
Rightware’s goal with Kanzi One is to inspire OEMs and Tier 1 suppliers with impressive rendering capabilities and a powerful 3D graphics engine, the deepest Android integration for next generation infotainment systems, and a straightforward workflow that unleashes HMI possibilities.
Kanzi One lets manufacturers deliver future-looking user experiences for advanced HMIs in less than half the time with teams half the size and with significantly less coding compared with traditional methods.
All-in-One Solution
In addition to the core Kanzi framework consisting of Kanzi Studio and Kanzi Engine, Kanzi One delivers further value to automakers by including a growing list of feature packs.
Initially, five feature packs are included: Kanzi Connect makes it easy to share data, content, and services across screens and devices; Kanzi Maps enhances navigation with creative visualization; Kanzi Particles enables astounding visual effects and animations; Kanzi Autostereoscopy enables realistic depth effects; and the new Kanzi VR makes it easy to validate designs in an early phase by placing live UIs inside a virtual car interior and interacting with the screens with or without a virtual reality headset.
“We are certain that Kanzi One will transform the in-car user interfaces of today into tomorrow’s Signature UIs—highly appealing, easy-to-use, and true to their brand,” said Geier. “We invite all friends and observers of innovation in the automotive industry to explore the possibilities of Kanzi One, and count on us to drive HMI development to the next level.”
Due to the rapidly rising health risks associated with covid, Rightware made the decision not to attend CES 2022. Instead, the company will kick off a customer road show to present Kanzi One as conditions permit. To request a virtual or in-person meeting and to read descriptions of the latest Kanzi One demonstrations, please visit www.rightware.com/kanzi-one-at-ces-2022 or contact sales@rightware.com .
About Rightware
Rightware is the company behind the Kanzi family of tools and services for design and development of advanced digital user interfaces. Our mission is to help automakers increase brand value with highly customized signature user interfaces. As a ThunderSoft company, our combined skills and assets allow us to deliver fully integrated HMI solutions, engineering support, and design services. Rightware is headquartered in Finland and has a presence in China, Germany, Italy, Japan, South Korea, UK, and USA. Kanzi is the market-leading automotive UI tool trusted by over 50 automotive brands across the globe. www.rightware.com
Android is a trademark of Google LLC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom